An oral gastrointestinal dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral gastrointestinal dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts； and (b) an oily medium consisting of: (i) one or more triglycerides formed from long chain fatty having from C13 to C24 carbon atoms； (ii) one or more mixed glycerides formed from long chain fatty having from C13 to C24 carbon atoms； and (iii) one or more free fatty acids formed from un-esterified long chain fatty acids having from C13 to C24 carbon atoms； and (c) about 10-60 wt % of a surfactant which promotes self-emulsification.
